Fig. 2From: Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIVSubgroup analysis of virologic outcomes throughout the study period. DTG dolutegravir, NRTI nucleoside reverse transcriptase inhibitor, DCR dolutegravir containing regimen, mono monotherapy, ABC abacavir, TDF tenofovir disoproxil fumarateBack to article page